PMID- 31906900
OWN - NLM
STAT- MEDLINE
DCOM- 20200529
LR  - 20200529
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 20
IP  - 1
DP  - 2020 Jan 6
TI  - Therapeutic effect against retinal neovascularization in a mouse model of 
      oxygen-induced retinopathy: bone marrow-derived mesenchymal stem cells versus 
      Conbercept.
PG  - 7
LID - 10.1186/s12886-019-1292-x [doi]
LID - 7
AB  - BACKGROUND: To study the therapeutic effect of bone marrow-derived mesenchymal 
      stem cells (BMSC) against retinal neovascularization and to compare with 
      anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Neonatal C57BL/6 
      mice were exposed in hyperoxygen and returned to room air to develop 
      oxygen-induced retinopathy (OIR). Red fluorescent protein-labeled BMSC and 
      Conbercept were intravitreally injected into OIR mice, respectively. Inhibition 
      of neovascularization and apoptosis in OIR mice were assessed through retinal 
      angiography, histopathology and terminal deoxynucleotidyl transferase-mediated 
      dUTP nick end labeling (TUNEL) assay. RESULTS: BMSC were able to migrate and 
      integrate into the host retina, significantly inhibit retinal neovascular tufts 
      and remodel the capillary network after injecton. Treatment with BMSC increased 
      the retinal vascular density, decreased the number of acellular capillaries and 
      inhibited retinal cell death. This effect was not inferior to current anti-VEGF 
      therapy by using Conbercept. CONCLUSIONS: Intravitreal injection of BMSC exerts a 
      protective effect against retinal neovascularization and offers a therapeutic 
      strategy for oxygen-induced retinopathy.
FAU - Xu, Wei
AU  - Xu W
AD  - Department of Ophthalmology, The First Affiliated Hospital of Fujian Medical 
      University, 20 Chazhong Road, Fuzhou City, 350005, China.
FAU - Cheng, Weijing
AU  - Cheng W
AD  - Department of Ophthalmology, The First Affiliated Hospital of Fujian Medical 
      University, 20 Chazhong Road, Fuzhou City, 350005, China.
AD  - Fujian Institute of Ophthalmology, Fuzhou, China.
FAU - Cui, Xiaoyuan
AU  - Cui X
AD  - Department of Ophthalmology, The First Affiliated Hospital of Fujian Medical 
      University, 20 Chazhong Road, Fuzhou City, 350005, China.
FAU - Xu, Guoxing
AU  - Xu G
AD  - Department of Ophthalmology, The First Affiliated Hospital of Fujian Medical 
      University, 20 Chazhong Road, Fuzhou City, 350005, China. fjmuxuguoxing@126.com.
AD  - Fujian Institute of Ophthalmology, Fuzhou, China. fjmuxuguoxing@126.com.
LA  - eng
GR  - 81770948/National Natural Science Foundation of China (CN)/
GR  - 2017-ZQN-42/Health Comission of Fujian Province/
GR  - 2017J05125/Natural Science Foundation of Fujian Province/
PT  - Journal Article
DEP - 20200106
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 1P05PW62F3 (KH902 fusion protein)
SB  - IM
MH  - Analysis of Variance
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Animals
MH  - Disease Models, Animal
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Recombinant Fusion Proteins/*therapeutic use
MH  - Retinal Neovascularization/*drug therapy
PMC - PMC6945477
OTO - NOTNLM
OT  - Mesenchymal stem cell
OT  - Oxygen-induced retinopathy
OT  - Retinal neovascularization
OT  - Therapy
OT  - Vascular endothelial growth factor
COIS- The authors declare that they have no competing interests.
EDAT- 2020/01/08 06:00
MHDA- 2020/05/30 06:00
PMCR- 2020/01/06
CRDT- 2020/01/08 06:00
PHST- 2019/03/13 00:00 [received]
PHST- 2019/12/27 00:00 [accepted]
PHST- 2020/01/08 06:00 [entrez]
PHST- 2020/01/08 06:00 [pubmed]
PHST- 2020/05/30 06:00 [medline]
PHST- 2020/01/06 00:00 [pmc-release]
AID - 10.1186/s12886-019-1292-x [pii]
AID - 1292 [pii]
AID - 10.1186/s12886-019-1292-x [doi]
PST - epublish
SO  - BMC Ophthalmol. 2020 Jan 6;20(1):7. doi: 10.1186/s12886-019-1292-x.